TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Child mental health measured by the Total Difficulties scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of overall GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HPV E6/E7 mRNA Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Step Length Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean total leukocytes and CD4+ T-cells expressing CCR5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Nugent's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of expression of 16S rRNA gene sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily physical activity in steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic control (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of skin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of the Patient Reported Outcome (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline of the Patient Reported Outcome (RADAI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline of the Patient Reported Outcome (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline of the Patient Reported Outcome (VAS-Patient)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity and specificity of Tc-99m perfusion scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stent malposition expressed as % of total stent area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of fetuses with abnormal fetal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in MDS-UPDRS Part II + Part III Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic Valvular Regurgitation at 6 Months Postprocedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic Valvular Regurgitation at 2 Years Postprocedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of the portable sleep study device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary immunodeficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbial colonisation change of S mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Surface roughness identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brown Attention Deficit Disorder Scale (BADDS) Change Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Physical activity (steps per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sleep disordered breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug's Breakpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Anxiety Rating Scale (PARS) severity score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Global Impression of Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post Traumatic Stress Disorder (PTSD) occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Recommendation of knee joint replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total number of split tests performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Venous Thromboembolism (VTE) Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: complete clearance of genital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: rate of hematological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rate of molecular remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: kinetics of the MRD of PML/RARa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: weekly physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of mammography screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total plasma fetuin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylated fetuin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22 (SNOT-22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Herth Hope Index (HHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resilience in Illness Scale (HARS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: number of subjects recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Participants Achieving ASAS 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral airway resistance (R5-R20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severe adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Anxiety and Depression Scale (HADS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical response on day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Direct all-cause medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Foot and Ankle Ability Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Lower Limb Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychomotor Development: Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neuropsychomotor Development: Receptive Language
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neuropsychomotor Development: Expressive Language
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neuropsychomotor Development: Fine Motor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neuropsychomotor Development: Gross Motor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evaluation of breast status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms in association with the ingestion of medicines that inhibit lactation
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of iTBS sessions
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of iTBS as a treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from biochemical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetics of actinomycin-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of Clinical Cancer Preventive Services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events outcomes without attribution
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events attributable
Endpoint domain: Adverse events/effects
Primary endpoint: Composition of the colonic microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of the microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracranial Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to complete a full examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal LIF levels during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maternal ACTH levels during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fetal LIF levels during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fetal ACTH levels during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in IL6 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of Moesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall symptoms of meralgia paresthetica
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Glabellar Frown Line (GFL) Responders at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Maintenance of Wakefulness Test (MWT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence of Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Eligible Participants Who Were Able to Attend an Appointment With a Physician
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time to first paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Body Mass Index Z-score Difference at 48-72 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index Z-score Difference at 10 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with dose limiting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with corneal adverse events impacting study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of overall response rate using standard imaging and RECIST v1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional Anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in pain and functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Negative re-biopsy rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants recruited based on region
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants with reported adherence to study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants attending all study visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ability to perform the endoscopic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change on the NIMH Trichotillomania Severity and Impairment Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-inflammatory mechanism evaluation at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanism evaluation at 48 hours after light delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-days mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe infection (SI) and/or non-injury death
Endpoint domain: Mortality/survival
Primary endpoint: ASL-derived cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggregate costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distance walked at 6-min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of stress-induced cortisol in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Timing of complete adenoma removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: International prostate symptoms score IPSS less than 7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: grade of bowel distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gene expression profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Six Minute Walking Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nijmegen Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in urine levels of F2-isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transcortical vessels and pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PONV incidence and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in non-vellus hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjects ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of new cases of Fabry disease diagnosed
Endpoint domain: Mortality/survival
Primary endpoint: Percent of infants who were stunted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of infants who were wasted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of infants who were underweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time (days) to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time (days) to lapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAT perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A2A receptor density in BAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with Systolic blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with Heart rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall response rate by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline Skindex-16 Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Diarrhea AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Seizure-free Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cytogenetic analyses of circulating CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut wall integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oxidative stress marker (MDA concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate (monthly)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant intervention satisfaction/evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in subacute discontinuation effects of MDMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Vascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in transcutaneous PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of treatment-emergent nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change of stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum change of cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of mean stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of mean cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative Incidence of Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Concentration of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of MTHFR mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: therapeutic improvement in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: drug abuse relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick-Dash
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects with Hepatitis B Reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Major Adverse Event (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in elektromyographic signal in peroneus longus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Parent's State Anxiety Inventory (STAI)-State score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vasomotor Symptoms (VMS) Frequency, Severity, and Bothersomeness During Daytime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Quality and Disturbances Over Past Month
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: prevalence of body impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medical Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reversal of abnormal metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of blood loss (mediastinal and pericardial tube drainage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surveillance with no progression
Endpoint domain: Mortality/survival
Primary endpoint: Positive Predictive Value (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes